MA-VERACODE
14.2.2024 13:51:34 CET | Business Wire | Press release
Veracode, a global leader in intelligent software security, today unveils its annual State of Software Security (SoSS) 2024 report, shedding light on the pressing issue of security debt in applications. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 42 percent of applications and 71 percent of organizations. Worryingly, 46 percent of organizations have persistent, high-severity flaws that constitute ‘critical’ security debt, putting businesses at serious risk in terms of impact on confidentiality, integrity, and availability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214981363/en/
State of Software Security 2024 Figure 25: Effect of flaw remediation speed on prevalence of security debt (Graphic: Business Wire)
According to the report, approximately 63 percent of applications have flaws in first-party code, while 70 percent contain flaws in third-party code imported via third-party libraries. This highlights the importance of testing both types throughout the software development life cycle. Remediation rates also vary by flaw type—fixing third-party flaws takes 50 percent longer, with half the known flaws fixed after 11 months, compared to seven months for first-party flaws.
There is good news, however: high-severity security flaws in applications have decreased by half since 2016, indicating progress in software security practices and that speed of remediation has a material impact on critical security debt.
SoSS 2024 reveals development teams that fix flaws the fastest reduce critical security debt by 75 percent—from 22.4 percent of applications to just over five percent. Moreover, these fast-acting teams are four times less likely to let critical security debt materialize in their applications in the first place.
Chris Eng, Chief Research Officer at Veracode, said, "While we continue to see improvements in the security landscape, these findings are a wake-up call for organizations to address their security debt head-on. By prioritizing flaw remediation, focusing on third-party code security, and adopting efficient development practices, organizations can significantly reduce their security debt and enhance the overall state of software security across the board."
Addressing AI and the Software Supply Chain
In an era where AI (artificial intelligence) is rapidly revolutionizing software development, the report highlights a concerning trend. Chris said, “Despite the speed and efficiency AI brings to software development, it does not necessarily produce code that’s secure. Research has shown that 36 percent of code generated by GitHub CoPilot contains security flaws.” This proliferation of insecure code at scale poses a significant risk to organizations and the software supply chain, leading to the accumulation of security debt over time.
Risk Prioritization is Key
Veracode’s research also found remediation capacity among teams to be constrained, with only 64 percent of applications having a remediation capacity that’s sufficient to eliminate critical security debt. In fact, only two out of ten applications show an average monthly fix rate that exceeds ten percent of all security flaws. This suggests, even in cases where teams’ fix capacity is sufficient, they are not prioritizing critical flaws.
Despite this, there is hope for success. Only three percent of all flaws constitute critical security debt, and this subset represents the largest risk exposure for applications. By prioritizing that three percent, organizations can achieve maximum risk reduction with focused effort.
Chris closed, "AI also paves the way for a new frontier in software security by empowering organizations to scale remediation efforts and more easily address the long backlog of security debt, as well as new flaws that emerge. The vast majority of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.”
The full State of Software Security 2024 report is available to download on the Veracode website. To access the report and gain deeper insights into the findings and recommendations, visit the website. A blog outlining the key findings from the report is also available to read.
-END-
About the State of Software Security Report
The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214981363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
